European Heart Journal · 2025 · 10 citations · 19 references
MedicineNephrologyRenal PathophysiologyRenal PharmacotherapyRenal Replacement TherapyChronic Kidney DiseaseDiabetic Kidney DiseaseRenal AssessmentRenal DiseaseRenal Function TestsRenal ImpairmentChronic Kidney Disease EpidemiologyClinical Risk ScoresPrimary Outcome AnalysisRisk Prediction ScoresRisk Score DevelopmentRisk Score EstimationRisk Stratification ScoresThiazide Diuretic Therapy
BACKGROUND AND AIMS: No tools are available for identifying patients with chronic kidney disease and Type 2 diabetes at high risk of hyperkalaemia. Using the FIDELITY pooled patient data set, a risk model for incident hyperkalaemia was developed and validated. METHODS: The primary outcome was new-onset hyperkalaemia (serum potassium >5.5 mmol/L). Data from the placebo arm were used for derivation and from the finerenone arm for validation. An integer risk score was built and divided into low-, intermediate-, and high-risk hyperkalaemia categories. Assessed efficacy outcomes included cardiovascular and kidney composites. RESULTS: Seven baseline covariates (serum potassium >4.5 mmol/L, prior history of hyperkalaemia, no sodium-glucose co-transporter-2 inhibitor use, urine albumin-to-creatinine ratio >1000 mg/g, haemoglobin <12 g/dL, no thiazide-type diuretic use, and estimated glomerular filtration rate <45 mL/min/1.73 m2) were independently associated with new-onset hyperkalaemia and used for building the integer risk model. The risk scores for derivation and validation were accurate and well calibrated. The derived integer score ranged from 0 to 12 points. The risk of new-onset hyperkalaemia increased across hyperkalaemia risk categories with 2.7, 7.0, and 16.7% of patients reporting a hyperkalaemia event in the low-risk (0-3 points), intermediate-risk (4-6 points), and high-risk (7-12 points) groups with placebo, respectively. Irrespective of hyperkalaemia risk, finerenone reduced cardiovascular and kidney events vs placebo. CONCLUSIONS: This integer risk score for new-onset hyperkalaemia in patients with chronic kidney disease and Type 2 diabetes could facilitate tailored treatment strategies and mitigate hyperkalaemia in high-risk patients.
19
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris, Rajiv Agarwal, Stefan D. Anker et al. · New England Journal of Medicine · 2020 · 2.6K citations · Full text